about
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.Development of new Malt1 inhibitors and probes.Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismMultiple myeloma: practice patterns across Europe.Spotlight on pomalidomide: could less be more?The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitorsPromising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myelomaStructure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i SubunitsAssociation of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerProlonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinomaManagement of cardiovascular risk in patients with multiple myelomaProteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome InhibitorsReplacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple MyelomaSpectrum and functional validation of PSMB5 mutations in multiple myelomaHuman leukocyte antigen variation is associated with adverse events of checkpoint inhibitorsSystemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumabIntegrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myelomaPrognostic impact of polypharmacy and drug interactions in patients with advanced cancerPredictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLCPrevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial HypertensionA metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesisUpdated recommendations for diagnosis and treatment of plasma cell myeloma in SwitzerlandNovel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myelomaNelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
P50
Q33437691-E3F279B4-31AE-45FA-AC5C-32AD087C99A7Q34999190-E3AB4EB5-A2E6-4123-B7DA-EC6F800E2FDCQ35991775-BC617002-8CC3-4C1C-AB66-DB1FB499E6DEQ37396016-38EDAF9B-ADE0-4DA6-B439-2CBAA5F933B3Q38862553-63EDB18D-4CA9-4D32-B656-A312CD9749A8Q41186724-C122A67E-8582-472A-B86D-0B7F7ED3925FQ41316676-A93F9830-5BEB-43BA-85F2-9ABAC1D9C269Q45324487-35F8A2EE-2E08-445A-BEE4-968324A6E427Q46185130-1EFF3583-FB74-44F8-90DF-78EE14C66EF6Q46813680-08D5EBC9-3ADF-4180-BCF4-1162794AB9B2Q46983477-A606E63C-8B74-402F-8BAA-7332013BEC58Q52801394-CD51A3AC-DCFA-4B4D-932D-E5A32EDADE03Q53800155-D5B13105-C15A-4574-88B7-6B20CB863646Q57180049-A588DEFC-84BF-4D4A-B64E-B54C30722FB4Q59795639-925442E2-C63D-4649-B688-3C552EBD174CQ61813541-CB7D4E12-5753-4216-8B1F-406F07FCD078Q64089344-E16A5E5E-E79E-44ED-BE77-1D8E142BAAA7Q64094384-59C352EA-DDEC-4C6B-A06D-550D18E96942Q64099073-B6A152A5-75E2-44FE-9E2E-62D42F56B18FQ64166856-C2EA22D2-6CBC-4ADA-9B47-6DA09591F5A9Q64243018-74396824-9389-4C79-BB4C-FC93349284E7Q90351167-6B3193ED-F0EA-4C39-88D0-D4FA601A7018Q90360609-30E3FAD3-7A36-4F45-B71C-38C8B54786AEQ90737042-39A257BC-38BC-483B-8EE1-3A52DAC9A839Q91167238-66F7F052-442C-4461-8C3F-39E406CF1AFCQ91229807-7CAF4206-782C-48B1-88D4-E6D5881EC0C1Q91346881-B6CD8004-F3AC-4E54-9196-7E794D6A19AEQ91375512-9D60A39F-DF24-4628-94D3-7E0E777926D8Q91813362-3CEC894C-C762-428C-9746-67316D65EBF8Q92821724-41264E06-BDCC-462F-B86B-0A4B8078D223Q92895845-26B12D32-1AF8-4778-B062-76F068435157Q92913475-1BC6C337-F30D-481E-88DE-17B05FFB129B
P50
description
researcher
@en
wetenschapper
@nl
name
C Driessen
@en
C Driessen
@nl
type
label
C Driessen
@en
C Driessen
@nl
prefLabel
C Driessen
@en
C Driessen
@nl
P31
P496
0000-0002-1124-7303